AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q3 FY20 results · Oct–Dec 2019
AstraZeneca Pharma India reported revenue from operations of ₹223.86 crore (up 4.0% from Q3 FY19) and net profit of ₹26.70 crore (down 8.2% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a standalone basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 223.86 | 215.19 | +4.0% | 208.48 | +7.4% |
| Other income | 3.46 | 3.50 | −1.0% | 3.16 | +9.5% |
| Total income | 227.32 | 218.69 | +3.9% | 211.64 | +7.4% |
| Profit before tax | 35.18 | 40.59 | −13.3% | 31.80 | +10.7% |
| Net profit for the period | 26.70 | 29.09 | −8.2% | 14.42 | +85.2% |
| EPS, basic (₹) | 10.68 | 11.64 | −8.2% | 5.77 | +85.2% |
| Net margin (%) | 11.9 | 13.5 | 6.9 |
Standalone
- Filed with BSE
- 04 Feb 2020, 10:43 IST
- Board meeting
- 03 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE